Riociguat (BAY 63-2521) is an sGC stimulator used for treating pulmonary hypertension that has attenuated cholestatic fibrogenesis and cirrhotic portal hypertension in rats [56,57]. This evidence concerns the gene SGCB and portal hypertension.